Chenevix-Trench G - Search Results

1

Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk.

Pearce CL, Doherty JA, Van Den Berg DJ, Moysich K, Hsu C, Cushing-Haugen KL, Conti DV, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Pharoah PD, Song H, Kjaer SK, Hogdall E, Hogdall C, Whittemore AS, McGuire V, Sieh W, Gronwald J, Medrek K, Jakubowska A, Lubinski J, Chenevix-Trench G; AOCS/ACS Study Group; Beesley J, Webb PM, Berchuck A, Schildkraut JM, Iversen ES, Moorman PG, Edlund CK, Stram DO, Pike MC, Ness RB, Rossing MA, Wu AH. Pearce CL, et al. Hum Mol Genet. 2011 Jun 1;20(11):2263-72. doi: 10.1093/hmg/ddr087. Epub 2011 Mar 21. Hum Mol Genet. 2011. PMID: 21422097 Free PMC article.

2

Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer.

Foster KA, Harrington P, Kerr J, Russell P, DiCioccio RA, Scott IV, Jacobs I, Chenevix-Trench G, Ponder BA, Gayther SA. Foster KA, et al. Cancer Res. 1996 Aug 15;56(16):3622-5. Cancer Res. 1996. PMID: 8705994

3

Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer.

Webb PM, Green A, Cummings MC, Purdie DM, Walsh MD, Chenevix-Trench G. Webb PM, et al. J Natl Cancer Inst. 1998 Nov 18;90(22):1729-34. doi: 10.1093/jnci/90.22.1729. J Natl Cancer Inst. 1998. PMID: 9827528

4

CYP17 promotor polymorphism and ovarian cancer risk.

Spurdle AB, Chen X, Abbazadegan M, Martin N, Khoo SK, Hurst T, Ward B, Webb PM, Chenevix-Trench G. Spurdle AB, et al. Int J Cancer. 2000 May 1;86(3):436-9. doi: 10.1002/(sici)1097-0215(20000501)86:3<436::aid-ijc21>3.0.co;2-a. Int J Cancer. 2000. PMID: 10760835

5

Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer.

Spurdle AB, Webb PM, Chen X, Martin NG, Giles GG, Hopper JL, Chenevix-Trench G. Spurdle AB, et al. Int J Cancer. 2000 Sep 1;87(5):637-43. Int J Cancer. 2000. PMID: 10925355

6

Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype.

Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. Spurdle AB, et al. Carcinogenesis. 2001 Jan;22(1):67-72. doi: 10.1093/carcin/22.1.67. Carcinogenesis. 2001. PMID: 11159743

7

The microsomal epoxide hydrolase Tyr113His polymorphism: association with risk of ovarian cancer.

Spurdle AB, Purdie DM, Webb PM, Chen X, Green A, Chenevix-Trench G. Spurdle AB, et al. Mol Carcinog. 2001 Jan;30(1):71-8. doi: 10.1002/1098-2744(200101)30:1<71::aid-mc1015>3.0.co;2-9. Mol Carcinog. 2001. PMID: 11255266

8

No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer.

Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. Spurdle AB, et al. Carcinogenesis. 2001 May;22(5):717-21. doi: 10.1093/carcin/22.5.717. Carcinogenesis. 2001. PMID: 11323389

9

BRCA2 Arg372Hispolymorphism and epithelial ovarian cancer risk.

Auranen A, Spurdle AB, Chen X, Lipscombe J, Purdie DM, Hopper JL, Green A, Healey CS, Redman K, Dunning AM, Pharoah PD, Easton DF, Ponder BA, Chenevix-Trench G, Novik KL. Auranen A, et al. Int J Cancer. 2003 Jan 20;103(3):427-30. doi: 10.1002/ijc.10814. Int J Cancer. 2003. PMID: 12471628

10

Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.

Berchuck A, Schildkraut JM, Wenham RM, Calingaert B, Ali S, Henriott A, Halabi S, Rodriguez GC, Gertig D, Purdie DM, Kelemen L, Spurdle AB, Marks J, Chenevix-Trench G. Berchuck A, et al. Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2141-7. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15598772

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

582 results

Search Page

Filters